Brain-gut interactions in IBS

Frontiers in Pharmacology

Volumn 3 JUL, Issue , 2012, Pages

  Fichna, Jakub ^a   Storr, Martin A ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Autonomic nervous system; Brain gut axis; Hypothalam opituitary adrenal axis; Irritable bowel syndrome; Pathophysiology

Indexed keywords

AZD 7371; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BUSPIRONE; CISAPRIDE; CORTICOTROPIN RELEASING FACTOR; PLACEBO; ROBALZOTAN; SEROTONIN 3 ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TOLL LIKE RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UROCORTIN;

ABDOMINAL PAIN; AGITATION; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD VESSEL INJURY; BRAIN GUT AXIS; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM; COGNITIVE THERAPY; COLON DILATATION; COMORBIDITY; CONSTIPATION; DRUG WITHDRAWAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HALLUCINATION; HEART DISEASE; HEART RATE VARIABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; INTESTINE INNERVATION; IRRITABLE COLON; NEUROIMMUNOLOGY; NEUROTRANSMISSION; NIGHTMARE; NOCICEPTION; NONHUMAN; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOSOCIAL DISORDER; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CONDUCTANCE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VISCERAL PAIN; XEROSTOMIA;

EID: 84866174286     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00127     Document Type: Article

References (182)

1. Adeyemo, M. A., Spiegel, B. M., and Chang, L. (2010). Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment. Pharmacol. Ther. 32, 738-755.
2. Aguilera, G., Subburaju, S., Young, S., and Chen, J. (2008). The parvo-cellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res. 170, 29-39.
3. Akira, S., and Takeda, K. (2004). Tolllike receptor signalling. Nat. Rev. Immunol. 4, 499-511.
4. Arborelius, L., Owens, M. J., Plotsky, P. M., and Nemeroff, C. B. (1999). The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160, 1-12.
5. Arebi, N., Gurmany, S., Bullas, D., Hobson, A., Stagg, A., and Kamm, M. (2008). Review article: the psy-choneuroimmunology of irritable bowel syndrome - an exploration of interactions between psychological, neurological and immunologi-cal observations. Aliment. Pharmacol. Ther. 28, 830-840.
6. Asagarasu, A., Matsui, T., Hayashi, H., Tamaoki, S., Yamauchi, Y., and Sato, M. (2009). Design and synthesis of piperazinylpyridine derivatives as novel 5-HT1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS). Chem. Pharm. Bull. 57, 34-42.
7. Atkinson, W., Lockhart, S., Whor-well, P. J., Keevil, B., and Houghton, L. A. (2006). Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130, 34-43.
8. Atkinson, W., Sheldon, T. A., Shaath, N., and Whorwell, P. J. (2004). Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 53, 1459-1464.
9. Azpiroz, F. (2002). Gastrointestinal perception: pathophysiological implications. Neurogastroenterol. Motil. 14, 229-239.
10. Azpiroz, F., Bouin, M., Camilleri, M., Mayer, E. A., Poitras, P., Serra, J., and Spiller, R. C. (2007). Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol. Motil. 19(1 Suppl.), 62-88.
11. Bale, T. L., and Vale, W. W. (2004). CRF andCRF receptors: roleinstress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44, 525-557.
12. Bannerman, D. M., Rawlins, J. N., McHugh, S. B., Deacon, R. M., Yee, B. K., Bast, T., Zhang, W. N., Pothuizen, H. H., and Feldon, J. (2004). Regional dissociations within the hippocampus - memory and anxiety. Neurosci. Biobehav. Rev. 28, 273-283.
13. Barbara, G., Cremon, C., De Giorgio, R., Dothel, G., Zecchi, L., Bellacosa, L., Carini, G., Stanghellini, V., and Corinaldesi, R. (2011). Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr. Gastroenterol. Rep. 13, 308-315.
14. Barbara, G., Stanghellini, V., De Giorgio, R., Cremon, C., Cottrell, G. S., Santini, D., Pasquinelli, G., Morselli-Labate, A. M., Grady, E. F., Bunnett, N. W., Collins, S. M., and Corinaldesi, R. (2004). Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroen-terology. 126, 693-702.
15. Barnes, N. M., Hales, T. G., Lummis, S. C., and Peters, J. A. (2009). The 5-HT3 receptor - the relation-shipbetween structure andfunction. Neuropharmacology. 56, 273-284.
16. Berman, S., Munakata, J., Naliboff, B. D., Chang, L., Mandelkern, M., Silverman, D., Kovalik, E., and Mayer, E. A. (2000). Gender differences in regional brain response to visceral pressure in IBS patients. Eur. J. Pain 4, 157-172.
17. Berman,S. M., Chang, L., Suyenobu, B., Derbyshire, S. W., Stains, J., Fitzgerald, L., Mandelkern, M., Hamm, L., Vogt, B., Naliboff, B. D., and Mayer, E. A. (2002). Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 123, 969-977.
18. Blankstein, U., Chen, J., Diamant, N. E., and Davis, K. D. (2010). Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology 138, 1783-1789.
19. Bravo, J. A., Dinan, T. G., and Cryan, J. F. (2011). Alterations in the central CRF system of two different rat models of comorbid depression and functional gastrointestinal disorders. Int. J. Neuropsychopharmacol. 14, 666-683.
20. Brint, E. K., MacSharry, J., Fanning, A., Shanahan, F., and Quigley, E. M. (2011). Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am. J. Gastroenterol. 106, 329-336.
21. Caldji, C., Diorio, J., and Meaney, M. J. (2000). Variations in maternal care in infancy regulate the development of stress reactivity. Biol. Psychiatry 48, 1164-1174.
22. Camilleri, M. (2011). LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol. Motil. 23, 193-200.
23. Camilleri, M., and Andresen, V. (2009). Current and novel therapeutic options for irritable bowel syndrome management. Dig. Liver Dis. 41, 854-862.
24. Camilleri, M., and Choi, M. G. (1997). Review article: irritable bowel syndrome. Aliment. Pharmacol. Ther. 11, 3-15.
25. Camilleri,M., Kerstens, R., Rykx, A., and Vandeplassche, L. (2008). A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358, 2344-2354.
26. Carter, D., Champney, M., Hwang, B., and Eglen, R. M. (1995). Characterization of a postjunctional 5-HT receptor mediating relaxation of guineapig isolated ileum. Eur. J. Pharmacol. 280, 243-250.
27. Chang, L., Mayer, E. A., Labus, J. S., Schmulson, M., Lee, O. Y., Olivas, T. I., Stains, J., and Naliboff, B. D. (2006). Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am. J. Phys-iol. Regul. Integr. Comp. Physiol. 291, R277-R284.
28. Chang, L., Sundaresh, S., Elliott, J., Anton, P. A., Baldi, P., Licudine, A., Mayer, M., Vuong, T., Hirano, M., Naliboff, B. D., Ameen, V. Z., and Mayer, E. A. (2009). Dys-regulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogas-troenterol. Motil. 21, 149-159.
29. Chang, L., Tong, K., and Ameen, V. (2010). Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am. J. Gastroenterol. 105, 866-875.
30. Chen, J. Y., Blankstein, U., Diamant, N. E., and Davis, K. D. (2011). White matter abnormalities in irritable bowel syndrome and relation to individual factors. Brain Res. 1392, 121-131.
31. Chey, W. D., Maneerattaporn, M., and Saad, R. (2011). Pharmaco-logic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 5, 253-266.
32. Clarke, G., Quigley, E. M., Cryan, J. F., and Dinan, T. G. (2009). Irritable bowel syndrome: towards biomarker identification. Trends Mol. Med. 15, 478-489.
33. Coates, M. D., Mahoney, C. R., Linden, D. R., Sampson, J. E., Chen, J., Blaszyk, H., Crowell, M. D., Sharkey, K. A., Gershon, M. D., Mawe, G. M., and Moses, P. L. (2004). Molecular defects in mucosal serotonin content and decreased serotonin reup-take transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126, 1657-1664.
34. Collins, S. M., and Bercik, P. (2009). The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003-2014.
35. Cryan, J. F., Valentino, R. J., and Lucki, I. (2005). Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29, 547-569.
36. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., and Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46-56.
37. Dautzenberg, F. M., Higelin, J., Wille, S., and Brauns, O. (2004). Molecular cloning and functional expression of the mouse CRF2(a) receptor splice variant. Regul. Pept. 121, 89-97.
38. Davis,K.D., Pope, G., Chen, J., Kwan,C. L., Crawley, A. P., and Diamant, N. E. (2008). Cortical thinning in IBS: implications for homeostatic, attention, and pain processing. Neurology 70, 153-154.
39. Dinan, T. G., Clarke, G., Quigley, E. M., Scott, L. V., Shanahan, F., Cryan, J., Cooney, J., and Keeling, P. W. (2008). Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of mus-carinic receptors. Am. J. Gastroen-terol. 103, 2570-2576.
40. Dinan, T. G., Quigley, E. M., Ahmed, S. M., Scully, P., O'Brien, S., O'Mahony, L., O'Mahony, S., Shanahan, F., and Keeling, P. W. (2006). Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130, 304-311.
41. Dorn, S. D., Palsson, O. S., Thiwan, S. I., Kanazawa, M., Clark, W. C., van Tilburg, M. A., Drossman, D. A., Scarlett, Y., Levy, R. L., Ringel, Y., Crowell, M. D., Olden, K. W., and Whitehead, W. E. (2007). Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 56, 1202-1209.
42. Drossman, D. A. (1998). Presidential address: gastrointestinal illness and the biopsychosocial model. Psycho-som. Med. 60, 258-267.
43. Drossman, D. A., Camilleri, M., Mayer, E. A., and Whitehead, W. E. (2002). AGA technical review on irritable bowel syndrome. Gastroenterology 123, 2108-2131.
44. Drossman, D. A., Creed, F. H., Olden, K. W., Svedlund, J., Toner, B. B., and Whitehead, W. E. (1999). Psychosocial aspects of the functional gastrointestinal disorders. Gut 45(Suppl. 2), 225-230.
45. Drossman, D. A., Danilewitz, M., Naesdal, J., Hwang, C., Adler, J., and Silberg, D. G. (2008). Randomized, double-blind, placebo-controlled trialof the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am. J. Gastroenterol. 103, 2562-2569.
46. Drossman, D. A., and Dumitrascu, D. L. (2006). Rome III new standard for functional gastrointestinal disorders. J. Gastrointestin. Liver Dis. 15, 237-241.
47. Drossman, D. A., Whitehead, W. E., Toner, B. B., Diamant, N., Hu, Y. J., Bangdiwala, S. I., and Jia, H. (2000). What determines severity among patients with painful functional bowel disorders? Am. J. Gastroenterol. 95, 974-980.
48. Dunlop, S. P., Coleman, N. S., Black-shaw, E., Perkins, A. C., Singh, G., Marsden, C. A., and Spiller, R. C. (2005). Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin. Gas-troenterol. Hepatol. 3, 349-357.
49. Elsenbruch, S., Lucas, A., Holtmann, G., Haag, S., Gerken, G., Riemen-schneider, N., Langhorst, J., Kave-laars, A., Heijnen, C. J., and Sched-lowski, M. (2006). Public speaking stress-induced neuroendocrine responses and circulating immune cell redistribution in irritable bowel syndrome. Am. J. Gastroenterol. 101, 2300-2307.
50. Engel, G. L. (1977). The need for a new medical model: a challenge for biomedicine. Science 196, 129-136.
51. Feldman, S., and Weidenfeld, J. (1998). The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic nor-epinephrine,serotonin,and CRF-41. Brain Res. Bull. 45, 389-393.
52. Fichna, J., Schicho, R., Janecka,A., Zjaw-iony, J. K., and Storr, M. (2009). Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News Perspect. 22, 383-392.
53. Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M., and Moayyedi, P. (2009). Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58, 367-378.
54. Fukudo, S. (2007). Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J. Gastroenterol. 42(Suppl. 17), 48-51.
55. Fukudo, S., and Kanazawa, M. (2011). Gene, environment, and brain-gut interactions in irritable bowel syndrome. J. Gastroenterol. Hepatol. 26(Suppl. 3), 110-115.
56. Fukudo, S., Nomura, T., and Hongo, M. (1998). Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42, 845-849.
57. Gaman, A., and Kuo, B. (2008). Neuromodulatory processes of the brain-gut axis. Neuromodulation 11, 249-259.
58. Garvin, B., and Wiley, J. W. (2008). The role of serotonin in irritable bowel syndrome: implications for management. Curr. Gastroenterol. Rep. 10, 363-368.
59. Gershon, M. D., and Tack, J. (2007). The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132, 397-414.
60. Greco, B., Allegretto, E. A., Tetel, M. J., and Blaustein, J. D. (2001). Coex-pression of ER beta with ER alpha and progestin receptor proteins in the female rat forebrain: effects of estradiol treatment. Endocrinology 142, 5172-5181.
61. Greenwood-Van, M. B., Gibson, M., Gunter, W., Shepard, J., Foreman, R., and Myers, D. (2001). Stereotaxic delivery of corticosterone to the amygdala modulates colonic sensitivity in rats. Brain Res. 893, 135-142.
62. Gros, D. F., Antony, M. M., McCabe, R. E., and Swinson, R. P. (2009). Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J. Anxiety Disord. 23, 290-296.
63. Grover, M., and Drossman, D. A. (2011). Centrally acting therapies for irritable bowel syndrome. Gas-troenterol. Clin. North Am. 40, 183-206.
64. Grundmann, O., Yoon, S. L., and Moshiree, B. (2010). Current developments for the diagnosis and treatment of irritable bowel syndrome. Curr. Pharm. Des. 16, 3638-3645.
65. Gue, M., Junien, J. L., and Bueno, L. (1991). Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology 100, 964-970.
66. Gustafsson, J. K., and Greenwood-Van, M. B. (2011). Amygdala activation by corticosterone alters visceral and somatic pain in cycling female rats. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G1080-G1085.
67. Gwee, K. A., Leong, Y. L., Graham, C., McKendrick, M. W., Collins, S. M., Walters, S. J., Underwood, J. E., and Read, N. W. (1999). The role of psychological and biological factors in postinfective gut dysfunction. Gut 44, 400-406.
68. Hall, G. B., Kamath, M. V., Collins, S., Ganguli, S., Spaziani, R., Miranda, K. L., Bayati, A., and Bienenstock, J. (2010). Heightened central affective response to visceral sensations of pain and discomfort in IBS. Neurogastroenterol. Motil. 22, 276-e80.
69. Herman, J. P., Figueiredo, H., Mueller, N. K., Ulrich-Lai, Y., Ostrander, M. M., Choi, D. C., and Cullinan, W. E. (2003). Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front. Neuroendocrinol. 24:7. doi:10.1016/j.yfrne.2003.07.001
70. Houghton, L. A., Lea, R., Jackson, N., and Whorwell,P.J. (2002).The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 50, 471-474.
71. Hsu, S. Y., and Hsueh, A. J. (2001). Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 7, 605-611.
72. Ibeakanma, C., Ochoa-Cortes, F., Miranda-Morales, M., McDonald, T., Spreadbury, I., Cenac, N., Ibeakanma, C., Ochoa-Cortes, F., Miranda-Morales, M., McDonald, T., Spreadbury, I., Cenac, N., Cattaruzza, F., Hurlbut, D., Vanner, S., Bunnett, N., Vergnolle, N., and Vanner, S. (2011). Braingut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology 141, 2098-2108.
73. Izzo, A. A., and Sharkey, K. A. (2010). Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. 126, 21-38.
74. Jarcho, J. M., Chang, L., Berman, M., Suyenobu, B., Naliboff, B. D., Lieber-man, M. D., Ameen,V. Z., Mandelk-ern, M. A., and Mayer, E. A. (2008). Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment. Pharmacol. Ther. 28, 344-352.
75. Jarrett, M. E., Burr, R. L., Cain, K. C., Hertig, V., Weisman, P., and Heitkemper, M. M. (2003). Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome. Dig. Dis. Sci. 48, 386-394.
76. John, C. D., and Buckingham, J. C. (2003). Cytokines: regulation of the hypothalamo - pituitary - adrenocortical axis. Curr. Opin. Pharmacol. 3, 78-84.
77. Johnson, A. C., Myers, B., Lazovic, J., Towner, R., and Greenwood-Van, M. B. (2010). Brain activation in response to visceral stimulation in rats with amygdala implants of corticosterone: an FMRI study. PLoS ONE 5, e8573. doi:10.1371/journal.pone.0008573
78. Kane, S. V., Sable, K., and Hanauer, S. B. (1998). The menstrual cycle and its effect oninflammatorybowel disease and irritable bowel syndrome: a prevalence study. Am. J. Gastroen-terol. 93, 1867-1872.
79. Kennedy, P. J., Clarke, G., Quigley, E. M., Groeger, J. A., Dinan, T. G., and Cryan, J. F. (2012). Gut memories: towards a cognitive neu-robiology of irritable bowel syndrome. Neurosci. Biobehav. Rev. 36, 310-340.
80. Khasar, S. G., Burkham, J., Dina, O. A., Brown, A. S., Bogen, O., Alessandri-Haber, N., Green, P. G., Reichling, D. B., and Levine, J. D. (2008). Stress induces a switch of intracellular sig-nalingin sensory neuron sin a model of generalized pain. J. Neurosci. 28, 5721-5730.
81. Kilpatrick, L. A., Ornitz, E., Ibrahi-movic, H., Treanor, M., Craske, M., Nazarian, M., Kilpatrick, L. A., Ornitz, E., Ibrahimovic, H., Treanor, M., Craske, M., Nazarian, M., Labus, J. S., Mayer, E. A., and Naliboff, B. D. (2010). Sex-related differences in prepulse inhibition of startle in irri table bowel syndrome (IBS). Biol. Psychol. 84, 272-278.
82. Kirby, L. G., Rice, K. C., and Valentino, R. J. (2000). Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 22, 148-162.
83. Kostich, W. A., Chen, A., Sperle, K., and Largent, B. L. (1998). Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol. Endocrinol. 12, 1077-1085.
84. Kozlowski, C. M., Green, A., Grundy, D., Boissonade, F. M., and Bountra, C. (2000). The 5-HT(3) receptor antagonist alosetron inhibits the col-orectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 46, 474-480.
85. Kwan, C. L., Diamant, N. E., Pope, G., Mikula, K., Mikulis, D. J., and Davis, K. D. (2005). Abnormal fore-brain activity in functional bowel disorder patients with chronic pain. Neurology 65, 1268-1277.
86. Labus, J. S., Naliboff, B. N., Fallon, J., Berman, S. M., Suyenobu, B., Bueller, J. A., Mandelkern, M., and Mayer, E. A. (2008). Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 41, 1032-1043.
87. Lackner, J. M., Lou, C. M., Mertz, H. R., Wack,D. S., Katz,L. A., Krasner,S. S., Firth, R., Mahl,T. C., andLockwood, A. H. (2006). Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Behav. Res. Ther. 44, 621-638.
88. Larauche, M., Mulak, A., and Tache, Y. (2012). Stress and visceral pain: from animal models to clinical therapies. Exp. Neurol. 233, 49-67.
89. Lawal, A., Kern, M., Sidhu, H., Hof-mann, C., and Shaker, R. (2006). Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 130, 26-33.
90. Lee, S. Y., Kim, J. H., Sung, I. K., Park, H. S., Jin, C. J., Choe, W. H., Kwon, S. Y., Lee, C. H., and Choi, K. W. (2007). Irritable bowel syndrome is more common in women regardless of the menstrual phase: a Rome II-based survey. J. Korean Med. Sci. 22, 851-854.
91. Lembo, T., Plourde, V., Shui, Z., Fullerton, S., Mertz, H., Tache, Y., Sytnik, B., Munakata, J., and Mayer, E. (1996). Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol. Motil. 8, 9-18.
92. Lewis, K., Li, C., Perrin, M. H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T. M., Gulyas, J., Fischer, W., Bilezikjian, L., Rivier, J., Sawchenko, P. E., and Vale, W. W. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98, 7570-7575.
93. Lindstrom, E., Ravnefjord, A., Brus-berg, M., Hjorth, S., Larsson, H., and Martinez, V. (2009). The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats. J. Pharmacol. Exp. Ther. 329, 1048-1055.
94. Lowry, C. A., and Moore, F. L. (2006). Regulation of behavioral responses by corticotropin-releasing factor. Gen. Comp. Endocrinol. 146, 19-27.
95. Lukkes, J. L., Forster, G. L., Renner, K. J., and Summers, C. H. (2008). Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. Eur. J. Pharmacol. 578, 185-193.
96. Mach, T. (2004). The brain-gut axis in irritable bowel syndrome - clinical aspects. Med. Sci. Monit. 10, RA125-RA131.
97. Manini, M. L., Camilleri, M., Goldberg, M., Sweetser, S., McKinzie, S., Burton, D., Wong, S., Kitt, M. M., Li, Y. P., and Zinsmeister, A. R. (2010). Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and phar-macokineticsinhealth and constipation. Neurogastroenterol. Motil. 22, 42-48.
98. Martinez, V., and Tache, Y. (2006). CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr. Pharm. Des. 12, 4071-4088.
99. Martinez, V., Wang, L., Rivier, J., Grigoriadis, D., and Tache, Y. (2004). Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. J. Physiol. (Lond.) 556(Pt 1), 221-234.
100. Mayer, E. A., and Collins, S. M. (2002). Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 122, 2032-2048.
101. Mayer, E. A., Naliboff, B., Lee, O., Munakata, J., and Chang, L. (1999). Review article: gender-related differences in functional gastrointestinal disorders. Aliment. Pharmacol. Ther. 13(Suppl. 2), 65-69.
102. Mayer, E. A., Naliboff, B. D., and Craig, A. D. (2006). Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 131, 1925-1942.
103. McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87, 873-904.
104. McKernan, D. P., Gaszner, G., Quigley, E. M., Cryan, J. F., and Dinan, T. G. (2011). Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 33, 1045-1052.
105. McKernan, D. P., Nolan, A., Brint, E. K., O'Mahony, S. M., Hyland, N. P., Cryan, J. F., and Dinan, T. G. (2009). Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS ONE 4, e8226. doi:10.1371/journal.pone.0008226
106. Mertz, H., Morgan, V., Tanner, G., Pick-ens, D., Price, R., Shyr, Y., and Kessler, R. (2000). Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 118, 842-848.
107. Meuser, T., Pietruck, C., Gabriel, A., Xie, G. X., Lim, K. J., and Pierce, P. P. (2002). 5-HT7 receptors are involved in mediating 5-HT-induced activation of rat primary afferent neurons. Life Sci. 71, 2279-2289.
108. Million, M., Grigoriadis, D. E., Sullivan, S., Crowe, P. D., McRoberts, J. A., Zhou, H., Saunders, P. R., Maillot, C., Mayer, E. A., and Taché, Y. (2003). A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res. 985, 32-42.
109. Milner, T. A., Lubbers, L. S., Alves, S. E., and McEwen, B. S. (2008). Nuclear and extranuclear estrogen binding sites in the rat forebrain and auto-nomic medullary areas. Endocrinology 149, 3306-3312.
110. Moreau, J. L., Kilpatrick, G., and Jenck, F. (1997). Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport 8, 1697-1701.
111. Morin, S. M., Ling, N., Liu, X. J., Kahl, S. D., and Gehlert, D. R. (1999). Dif ferential distribution of urocortin-and corticotropin-releasing factor-like immunoreactivities in the rat brain. Neuroscience 92, 281-291.
112. Mulak, A., and Bonaz, B. (2004). Irritable bowel syndrome: a model of the brain-gut interactions. Med. Sci. Monit. 10, RA55-RA62.
113. Mulak, A., and Paradowski, L. (2006). Effect of 5-HT1 agonist (sumatriptan) on anorectal function in irritable bowel syndrome patients. World J. Gastroenterol. 12, 1591-1596.
114. Myers, B., and Greenwood-Van, M. B. (2007). Corticosteroid receptor-mediated mechanisms in the amygdala regulate anxiety and colonic sensitivity. Am. J. Physiol. Gastroin-test. Liver Physiol. 292, G1622- G1629.
115. Myers, B., and Greenwood-Van, M. B. (2009). Role of anxiety in the pathophysiology of irritable bowel syndrome: importance of the amygdala. Front. Neurosci. 3:47. doi:10.3389/neuro.21.002.2009
116. Myers, B., and Greenwood-Van, M. B. (2010). Elevated corticosterone in the amygdala leads to persis tent increases in anxiety-like behav ior and pain sensitivity. Behav. Brain Res. 214, 465-469.
117. Myers, B., Schulkin, J., and Greenwood-Van, M. B. (2011). Sex steroids localized to the amygdala increase pain responses to visceral stimulation in rats. J. Pain. 12, 486-494.
118. Naliboff, B. D., Berman, S., Chang, L., Derbyshire, S. W., Suyenobu, B., Vogt, B. A., Mandelkern, M., and Mayer, E. A. (2003). Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 124, 1738-1747.
119. Naliboff, B. D., Derbyshire, S. W., Munakata, J., Berman, S., Mandelkern, M., Chang, L., and Mayer, E. A. (2001). Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psy-chosom. Med. 63, 365-375.
120. Niddam, D. M., Tsai, S. Y., Lu, C L., Ko, C. W., and Hsieh, J. C. (2011). Reduced hippocampal glutamate-glutamine levels in irri table bowel syndrome: preliminary findings using magnetic resonance spectroscopy. Am. J. Gastroenterol. 106, 1503-1511.
121. Ohman, L., and Simren, M. (2010). Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat. Rev. Gastroenterol. Hepatol. 7, 163-173.
122. O'Mahony,S.M.,Bulmer,D.C.,Coelho, A. M., Fitzgerald, P., Bongiovanni, C., Lee, K., Winchester, W., Dinan, T. G., and Cryan, J. F. (2010a). 5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol. Motil. 22, 573-578, e124.
123. O'Mahony, S.M., Bulmer, D.C., Coelho, A. M., Fitzgerald, P., Bongiovanni, C., Lee, K., Winchester, W., Dinan, T. G., and Cryan, J. F. (2010b). 5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol. Motil. 22, 573-578, e124.
124. O'Mahony, S. M., Hyland, N. P., Dinan, T. G., and Cryan, J. F. (2011). Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl.) 214, 71-88.
125. Owens, M. J., and Nemeroff, C. B. (1993). The role of corticotropin-releasing factor in the pathophys-iology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found. Symp. 172, 296-308.
126. Pandey, S. C., Zhang, H., Roy, A., and Misra, K. (2006). Central and medial amygdaloid brain-derived neurotrophic factor signaling plays a critical role in alcohol-drinking and anxiety-like behaviors. J. Neurosci. 26, 8320-8331.
127. Penalva, R. G., Flachskamm, C., Zimmermann, S., Wurst, W., Holsboer, F., Reul, J. M., and Linthorst, A. C. (2002). Corticotropin-releasing hormone receptor type 1-deficiency enhances hippocampal serotonergic neurotransmission: an in vivo microdialysis study in mutant mice. Neuroscience 109, 253-266.
128. Philpott, H., Gibson, P., and Thien, F. (2011). Irritable bowel syndrome - an inflammatory disease involving mast cells. Asia Pac. Allergy 1, 36-42.
129. Piche, M., Bouin, M., Arsenault, M., Poitras, P., and Rainville, P. (2011). Decreased pain inhibition in irritable bowel syndrome depends on altered descending modulation and higher-order brain processes. Neuro-science 195, 166-175.
130. Prado,W.A.,and Roberts, M.H. (1985). An assessment of the antinociceptive and aversive effects of stimulating identified sites in the rat brain. Brain Res. 340, 219-228.
131. Price, M. L., Curtis, A. L., Kirby, L. G., Valentino, R. J., and Lucki, I. (1998). Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 18, 492-502.
132. Rapps, N., van Oudenhove, L., Enck, P., and Aziz, Q. (2008). Brain imaging of visceral functions in healthy volunteers and IBS patients. J. Psychosom. Res. 64, 599-604.
133. Redgate, E. S., and Fahringer, E. E. (1973). A comparison of the pituitary adrenal activity elicited by electrical stimulation of preoptic, amygdaloid and hypothalamic sites in the ratbrain.Neuroendocrinology 12, 334-343.
134. Ren, T. H., Wu, J., Yew, D., Ziea, E., Lao, L., Leung, W. K., Berman, B., Hu, P. J., and Sung, J. J. (2007). Effects of neonatal maternal separation on neurochemicaland sensoryresponse to colonic distension in a rat model of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G849-G856.
135. Reyes, T. M., Lewis, K., Perrin, M. H., Kunitake, K. S., Vaughan, J.,Arias, C. A., Hogenesch, J. B., Gulyas, J., Riv-ier, J., Vale, W. W., and Sawchenko, P. E. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98, 2843-2848.
136. Ribeiro, S. C., Kennedy, S. E., Smith, Y. R., Stohler, C. S., and Zubieta, J. K. (2005). Interface of physical and emotional stress reg ulation through the endogenous opioid system and mu-opioid receptors Prog Neuropsy-chopharmacol. Biol. Psychiatry 29, 1264-1280.
137. Ringel,Y. (2002). Brain research in functional gastrointestinal disorders. J. Clin. Gastroenterol. 35(1 Suppl.), S23-S25.
138. Ringel, Y., Drossman, D. A., Leserman, J. L., Suyenobu, B. Y., Wilber, K., Lin, W., Whitehead, W. E., Naliboff, B. D., Berman, S., and Mayer, E. A. (2008). Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 134, 396-404.
139. Rosas-Ballina, M., and Tracey, K. J. (2009). The neurology of the immune system: neural reflexes regulate immunity. Neuron 64, 28-32.
140. Sagami, Y., Shimada, Y., Tayama, J., Nomura, T., Satake, M., Endo, Y., Shoji, T., Karahashi, K., Hongo, M., and Fukudo, S. (2004). Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53, 958-964.
141. Saito, K., Kanazawa, M., and Fukudo, S. (2002). Colorectal distention induces hippocampal noradrenaline release in rats: an in vivo microdialysis study. Brain Res. 947, 146-149.
142. Salari, P., and Abdollahi, M. (2011). Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J. Gastroenterol. 17, 4251-4257.
143. Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., and Rubin, R. (2002). The burden of selected digestive diseases in the United States. Gastroenterol-ogy 122, 1500-1511.
144. Saunders, P. R., Maillot, C., Million, M., and Tache, Y. (2002). Peripheral corticotropin-releasing factor induces diarrhea in rats: role of CRF1 receptor in fecal watery excretion. Eur. J. Pharmacol. 435, 231-235.
145. Seminowicz, D. A., Labus, J. S., Bueller, J. A., Tillisch, K., Naliboff, B. D., Bushnell, M. C., and Mayer, E. A. (2010). Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 139, 48-57.
146. Shepard,J.D., Barron,K.W.,and Myers, D. A. (2003). Stereotaxic localization of corticosterone to the amygdala enhances hypothalamo-pituitaryadrenal responses to behavioral stress. Brain Res. 963, 203-213.
147. Sivarao, D. V., Newberry, K., and Lodge, N. J. (2004). Effect of the 5HT1A receptor partial agonist bus-pirone on colorectal distension-induced pseudoaffective and behavioral responses in the female Wistar rat. Eur. J. Pharmacol. 494, 23-29.
148. Slack, S. E., Pezet, S., McMahon, S. B., Thompson, S. W., and Mal-cangio, M. (2004). Brain-derived neurotrophic factor induces NMDA receptor subunit one phosphoryla-tion via ERK and PKC in the rat spinal cord. Eur. J. Neurosci. 20, 1769-1778.
149. Slawecki, C. J., Somes, C., Rivier, J. E., and Ehlers,C. L. (1999). Neurophys-iological effects of intracerebroven-tricular administration of urocortin. Peptides 20, 211-218.
150. Smith, G. W., Aubry, J. M., Dellu, F., Contarino, A., Bilezikjian, L. M., Gold, L. H., Chen, R., Marchuk, Y., Hauser, C., Bentley, C. A., Sawchenko, P. E., Koob, G. F., Vale, W., and Lee, K. F. (1998). Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroen-docrine development. Neuron 20, 1093-1102.
151. Southwick, S. M., Bremner, J. D., Ras-musson, A., Morgan, C. A. III, Arnsten, A., and Charney, D. S. (1999). Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol. Psychiatry 46, 1192-1204.
152. Spaziani, R., Bayati, A., Redmond, K., Bajaj, H., Mazzadi, S., Bienenstock, J., Collins, S. M., and Kamath, M. V. (2008). Vagal dysfunctioninirritable bowel syndrome assessed by rectal distension and baroreceptor sensitivity. Neurogastroenterol. Motil. 20, 336-342.
153. Spiller, R. (2007). Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol. Motil. 19(Suppl. 2), 25-31.
154. Spiller, R., and Garsed, K. (2009). Infection, inflammation, and the irritable bowel syndrome. Dig. Liver Dis. 41, 844-849.
155. Sweetser, S., Camilleri, M., Linker Nord, S. J., Burton, D. D., Castenada, L., Croop,R.,Tong,G.,Dockens,R.,and Zinsmeister, A. R. (2009). Do cor-ticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am. J. Phys-iol. Gastrointest. Liver Physiol. 296, G1299-G1306.
156. Tache, Y., and Brunnhuber, S. (2008). From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases. Ann. N. Y. Acad. Sci. 1148, 29-41.
157. Tache, Y., Kiank, C., and Stengel, A. (2009). A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr. Gastroenterol. Rep. 11, 270-277.
158. Tache, Y., Martinez, V., Million, M., and Maillot, C. (2002). Role of cor-ticotropin releasing factor receptor subtype 1instress-related functional colonic alterations: implications in irritable bowel syndrome. Eur. J. Surg. 168 (Suppl. 1), 16-22.
159. Tache, Y., Martinez, V., Wang, L., and Million, M. (2004). CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br. J. Pharmacol. 141, 1321-1330.
160. Tack, J., Broekaert, D., Fischler, B., van Oudenhove, L., Gevers, A. M., and Janssens, J. (2006). A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 55, 1095-1103.
161. Tack, J., Coulie, B., Wilmer, A., Andri-oli, A., and Janssens, J. (2000). Influence of sumatriptan on gastric fun-dus tone and on the perception of gastric distension in man. Gut 46, 468-473.
162. Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflammation. Cell 140, 805-820.
163. Thompson, W. G., Heaton, K. W., Smyth, G. T., and Smyth, C. (2000). Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 46, 78-82.
164. Tillisch, K., Labus, J., Nam, B., Bueller, J., Smith, S., Suyenobu, B., Sif-fert, J., McKelvy, J., Naliboff, B., and Mayer, E. (2012). Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment. Pharmacol. Ther. 35, 360-367.
165. Tillisch, K., Mayer, E. A., and Labus, J. S. (2011). Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 140, 91-100.
166. Tillisch, K., Mayer, E. A., Labus, J. S., Stains, J., Chang, L., and Naliboff, B. D. (2005). Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 54, 1396-1401.
167. Tjong, Y. W., Ip, S. P., Lao, L., Wu, J., Fong, H. H., Sung, J. J., Berman, B., and Che, C. T. (2010). Neonatal maternal separation elevates thalamic corticotrophin releasing factor type 1 receptor expression response to colonic distension in rat. Neuro Endocrinol. Lett. 31, 215-220.
168. Toner, B. B., Segal, Z. V., Emmott, S., Myran, D., Ali, A., DiGas-barro, I., and Stuckless, N. (1998). Cognitive-behavioral group therapy for patients with irritable bowel syndrome. Int. J. Group Psychother. 48, 215-243.
169. Trimble, N., Johnson, A. C., Foster, A., and Greenwood-Van, M. B. (2007). Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. Neurogastroenterol. Motil. 19, 754-760.
170. Tyler, K., Moriceau, S., Sullivan, R. M., and Greenwood-Van, M. B. (2007). Long-term colonic hyper-sensitivity in adult rats induced by neonatal unpredictable vs predictable shock. Neurogastroenterol. Motil. 19, 761-768.
171. Vale, W., Spiess, J., Rivier, C., and Riv-ier, J. (1981). Characterization of a 41-residue ovine hypothalamic pep-tide that stimulates secretion of cor-ticotropin and beta-endorphin. Science 213, 1394-1397.
172. Valentino, R. J., and Commons, K. G. (2005). Peptides that fine-tune the serotonin system. Neuropeptides 39, 1-8.
173. Vanhoenacker, P., Haegeman, G., and Leysen, J. E. (2000). 5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol. Sci. 21, 70-77.
174. Venkova, K., Johnson, A. C., Myers, B., and Greenwood-Van, M. B. (2010). Exposure of the amygdala to elevated levels of corti-costerone alters colonic motility in response to acute psychological stress. Neuropharmacology 58, 1161-1167.
175. Vera-Portocarrero, L. P., Ossipov, M. H., King, T., and Porreca, F. (2008). Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology 135, 1369-1378.
176. Vetter, D. E., Li, C., Zhao, L., Contarino, A., Liberman, M. C., Smith, G. W., Marchuk, Y., Koob, G. F., Heinemann, S. F., Vale, W., and Lee,K. F. (2002). Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat. Genet. 31, 363-369.
177. Videlock, E. J., Adeyemo, M., Licudine, A., Hirano, M., Ohning, G., Mayer, M., Mayer, E. A., and Chang, L. (2009). Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterol-ogy 137, 1954-1962.
178. Wilder-Smith, C. H., Schindler, D., Lovblad, K., Redmond, S. M., and Nirkko, A. (2004). Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 53, 1595-1601.
179. Winston, J. H., Xu, G. Y., and Sarna, S. K. (2010). Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroen-terology 138, 294-304.
180. Yu, Y. B., Zuo, X. L., Zhao, Q. J., Chen, F. X., Yang, J., Dong, Y. Y., Wang, P., and Li, Y.Q. (2012). Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 61, 685-694.
181. Zisterer, D. M., and Williams, D. C. (1997). Peripheral-type benzodi-azepine receptors. Gen. Pharmacol. 29, 305-314.
182. Zou, B. C., Dong, L., Wang, Y., Wang, S. H., and Cao, M. B. (2007). Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. Chin. Med. J. 120, 2069-2074.